Company: SMNR
Filing Date: 2025-08-22
Form Type: 8-K
Source: 0001213900-25-079504
Chunk: 2

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-08-22
Form: 8-K
Item: Item 3.02
Chunk 2
---
Item
3.02 Unregistered Sales of Equity Securities.

The
information regarding the Purchase Agreement and the PIPE Financing set forth in Item 1.01 of this Current Report on Form 8-K is incorporated
by reference into this Item 3.02.

The
PIPE Shares to be issued in the PIPE Financing will not be registered under the Securities Act of 1933, as amended (the “ Securities
Act”), in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act and/or Rule 506(b) of Regulation
D promulgated thereunder. The Company will rely on this exemption from registration based in part on representations made by the Purchaser
in the Purchase Agreement, including that the Purchaser is an “accredited investor” as defined in Rule 501(a) of Regulation
D and is acquiring the securities for investment purposes and not with a view to distribution. The offering of the PIPE Shares was not
a public offering and was not accompanied by any general solicitation or advertising. The PIPE Shares will be restricted securities and
subject to transfer restrictions.

Additional
Information and Where to Find It

In
connection with the Business Combination, the Company filed with the U. S. Securities and Exchange Commission (the “ SEC”)
a registration statement on Form S-4 (the “ Registration Statement”), which included a preliminary proxy statement/prospectus
as well as other relevant information concerning the Business Combination. The SEC declared the Registration Statement effective on August
12, 2025, and the Company filed a definitive proxy statement/prospectus with the SEC on August 13, 2025. The Company commenced mailing
the definitive proxy statement/prospectus to the Company’s shareholders of record as of August 12, 2025, on or about August 13,
2025. This communication is not a substitute for the Registration Statement, the definitive proxy statement/prospectus or any other document
that the Company will send to its shareholders in connection with the Business Combination. Investors and security holders of the Company
are advised to read the definitive proxy statement/prospectus in connection with the Company’s solicitation of proxies for its
extraordinary general meeting of shareholders to be held to approve the Business Combination (and related matters) because the definitive
proxy statement/prospectus contains important information about the Business Combination and the parties to the Business Combination.
Shareholders are also able to obtain copies of the definitive proxy statement/prospectus, without charge, at the SEC’s